Alzheimer's Disease (AD), Alzheimer Type Dementia
Conditions
Keywords
Alzheimer's Disease, Ketogenic Diet, Intermittent Fasting, Ketoflex 12/3, Cognitive Decline, Neurodegeneration
Brief summary
This study investigates the effects of the Ketoflex 12/3 diet on the clinical progression of early-to-mid stage Alzheimer's disease. The study evaluates cognitive function, metabolic changes, and overall health outcomes in participants following the Ketoflex 12/3 dietary protocol.
Interventions
BEHAVIORALKetoflex 12/3 Diet
plant-based ketogenic diet combined with intermittent fasting (12/3)
Sponsors
Prof. Lutfu Hanoglu, MD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Age between 50-85 years * Clinical Dementia Rating (CDR) score of 1 or2 * Diagnosis of Alzheimer's disease (AD) according to NIA-AA criteria
Exclusion criteria
* Alcohol and/or substance dependence * Diagnosis of chronic renal failure * Diagnosis of another neuropsychiatric disorder * Presence of amalgam dental fillings and/or failure to have them removed following the SMART protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Cognitive Function as Measured by the MMSE Score | Baseline and 6 months | Mini-Mental State Examination (MMSE) will be used to assess cognitive function before and after the intervention. The Mini-Mental State Examination (MMSE) is used to assess cognitive function. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance. |
Countries
Turkey (Türkiye)
Contacts
PRINCIPAL_INVESTIGATORLütfü Hanoğlu, Prof. MD
Medipol University
Outcome results
None listed